CCM
SNTI icon

CAAS Capital Management’s Senti Biosciences Holdings SNTI Stock Holding History

CAAS Capital Management’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-75,668
Closed -$1.49M – 992
2022
Q2 		$1.49M Buy
+75,668
New +$6.08M 0.07% 296
2021
Q3 		– Sell
-9,290
Closed -$923K – 1100
2021
Q2 		$923K Buy
+9,290
New +$927K 0.02% 599

Other funds holding SNTI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $621M AUM 34.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

CAAS Capital Management's SNTI Position: Q3 2022 in Review

CAAS Capital Management sold out of Senti Biosciences Holdings (SNTI) in Q3 2022, closing a stake of 75,668 shares — an estimated $1.49M sold.

CAAS Capital Management first reported a position in SNTI in Q2 2021 and held it in 2 quarters. The position peaked at $1.49M in Q2 2022. 23 funds tracked by Wall St. Rank hold SNTI as of Q3 2022.

  • CAAS Capital Management reported no remaining Senti Biosciences Holdings position as of Q3 2022 after selling out during the quarter.
  • CAAS Capital Management sold 75,668 Senti Biosciences Holdings shares in Q3 2022, an estimated $1.49M.
  • CAAS Capital Management first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Senti Biosciences Holdings position peaked at $1.49M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q3 2022.

Based on CAAS Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.